In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell ...

A new experimental vaccine developed by researchers at MIT and Caltech could offer protection against emerging variants of SARS-CoV-2, as well as related coronaviruses, known as sarbecoviruses, that ...

Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated ...

Researchers from the Massachusetts Institute of Technology (MIT) and the California Institute of Technology (Caltech) have made significant strides in vaccine development that could protect against ...

Enhances B Cell Responses in Type 2 Inflammation Through IL-17RB Receptor,” published in the January 2025 issue of Allergy ...

Now, Honigberg and colleagues describe an orally available, potent and selective inhibitor of the B-cell receptor (BCR) signalling molecule Bruton's tyrosine kinase (BTK), which shows promising ...

Dr. David A Braun delved into detail on the molecular factors driving exceptional responses to immunotherapy in metastatic ...

a 3-year single center retrospective study of CD19-directed chimeric antigen receptor T-cell therapy for relapsed and refractory B-cell lymphomas, Haematologica (2024). DOI: 10.3324/haematol.

Figure 4: Impaired antigen receptor–activated B cell proliferation and humoral responses in Vav-deficient mice. Figure 5: Vav-2 in BCR signaling and tyrosine phosphorylation in Vav-1 −/− Vav ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...